| 1 |
Design of substrate-based BCR-ABL kinase inhibitors using the cyclotide scaffold. Sci Rep. 2015 Aug 12;5:12974.
|
| 2 |
Design of a novel cyclotide-based CXCR4 antagonist with anti-human immunodeficiency virus (HIV)-1 activity. J Med Chem. 2012 Dec 13;55(23):10729-34.
|
| 3 |
Cyclic thrombospondin-1 mimetics: grafting of a thrombospondin sequence into circular disulfide-rich frameworks to inhibit endothelial cell migration. Biosci Rep. 2015 Oct 13;35(6):e00270.
|
| 4 |
Design of a MCoTI-Based Cyclotide with Angiotensin (1-7)-Like Activity. Molecules. 2016 Jan 26;21(2):152.
|
| 5 |
Engineered cystine knot miniproteins as potent inhibitors of human mast cell tryptase beta. J Mol Biol. 2010 Jan 8;395(1):167-75.
|
| 6 |
In vivo activation of the p53 tumor suppressor pathway by an engineered cyclotide. J Am Chem Soc. 2013 Aug 7;135(31):11623-11633.
|
| 7 |
Design of a cyclotide antagonist of neuropilin-1 and -2 that potently inhibits endothelial cell migration. ACS Chem Biol. 2013;8(6):1147-54.
|
| 8 |
Using the MCoTI-II Cyclotide Scaffold To Design a Stable Cyclic Peptide Antagonist of SET, a Protein Overexpressed in Human Cancer. Biochemistry. 2016 Jan 19;55(2):396-405.
|
| 9 |
Engineering stabilized vascular endothelial growth factor-A antagonists: synthesis, structural characterization, and bioactivity of grafted analogues of cyclotides. J Med Chem. 2008 Dec 25;51(24):7697-704.
|
